1. Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors
- Author
-
Gandini, Annachiara, Bartolini, Manuela, Tedesco, Daniele, Martinez-Gonzalez, Loreto, Roca, Carlos, Campillo, Nuria E., Zaldivar-Diez, Josefa, Perez, Concepción, Zuccheri, Giampaolo, Miti, Andrea, Feoli, Alessandra, Castellano, Sabrina, Petralla, Sabrina, Monti, Barbara, Rossi, Martina, Moda, Fabio, Legname, Giuseppe, Martinez, Ana, and Bolognesi, Maria Laura
- Abstract
Several findings propose the altered tau protein network as an important target for Alzheimer’s disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process. On the basis of this consideration and on our interest in multitarget paradigms in AD, we report on the discovery of 2,4-thiazolidinedione derivatives endowed with such a profile. 28and 30displayed micromolar IC50values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, respectively. In addition, they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30also displayed inhibition of both K18 and full-length tau aggregations. Finally, both compounds were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model. To the best of our knowledge, 28and 30are the first balanced, nontoxic, dual-acting compounds hitting tau cascade at two different hubs.
- Published
- 2018
- Full Text
- View/download PDF